Κ-opioid receptor - an overview | ScienceDirect Topics
Nalfurafine, a G-Protein–Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics | Hypertension
κ-Opioid Receptor (KOP) | 7TM Antibodies
Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design | Scientific Reports
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
Understanding opioids in veterinary medicine
Frontiers | The Kappa Opioid Receptor: From Addiction to Depression, and Back
Table II from Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. | Semantic Scholar
Effects of the kappa opioid receptor agonist nalfurafine on IFN-γ⁺CD4⁺... | Download Scientific Diagram
The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence - Biological Psychiatry
Antagonists of the kappa opioid receptor - ScienceDirect
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports
Opioids in cancer: The κ‑opioid receptor (Review)
Kappa Opiate Receptor Agonist - an overview | ScienceDirect Topics
Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Figure 2 from Development of κ opioid receptor antagonists. | Semantic Scholar
κ-opioid receptor - Wikipedia
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports
Characterization of Pyrrolidinyl-hexahydro-pyranopiperazines as a Novel Kappa Opioid Receptor Agonist Scaffold | ACS Chemical Neuroscience
Innovation – Cara Therapeutics
